<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00152776</url>
  </required_header>
  <id_info>
    <org_study_id>HD04</org_study_id>
    <nct_id>NCT00152776</nct_id>
  </id_info>
  <brief_title>Treating Climacteric Symptoms With a Complex Homeopathic Remedy</brief_title>
  <official_title>Treatment of Climacteric Symptoms With Ovaria Comp - A Prospective Randomized Placebo Controlled Doubleblind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wala GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ovaria comp. is effective in relieving
      climacteric symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Complementary treatments for climacteric symptoms are used by many women although their
      efficacy and safety is mostly unproven.

      The use of the complex homeopathic remedy Ovaria comp. for the relief of climacteric symptoms
      will be examined in this three-armed intervention trial and measured with the menopause
      rating scale II before and after each study phase of 12 weeks. Participants will receive the
      verum during two treatment phases of 12 weeks and the placebo during one treatment phase of
      12 weeks in different sequences and are stratified for post- and perimenopausal status.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Climacteric symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>sum score of the menopause rating scale (MRS II) before and after 12 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Climacteric symptoms (vegetative, psychological, urogenital subscales of the MRS II)</measure>
    <time_frame>12 weeks</time_frame>
    <description>difference of the subscales of the menopause rating scale before and after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up for another 12 weeks of treatment or after cross-over to the placebo group</measure>
    <time_frame>12+12 weeks</time_frame>
    <description>sum score and subscales of the MRS II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up for cross-over to placebo after 24 weeks of treatment</measure>
    <time_frame>12+12+12 weeks</time_frame>
    <description>sum score and subscales of the MRS II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diurnal profile of cortisol level before and after treatment phases</measure>
    <time_frame>12+12+12 weeks</time_frame>
    <description>cortisol (saliva: morning, noon, evening)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression measured by Hospital Anxiety and Depression Scale (HADS-D) before and after treatment period</measure>
    <time_frame>12+12+12 weeks</time_frame>
    <description>Hospital Anxiety and Depression Scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Menopause</condition>
  <condition>Anxiety Disorders</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ovaria comp 10 Globuli 3 times per day 24 weeks - Placebo 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 12 weeks - ovaria comp 10 globuli 3 times per day 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ovaria comp 10 globuli 3 times per day 12 weeks - Placebo 12 weeks - ovaria comp 10 globuli 3 times per day 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ovaria comp 10 globuli 3 times per day 24 weeks</intervention_name>
    <description>order of intervention and placebo varies between Groups I-III</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_label>Group III</arm_group_label>
    <other_name>placebo globuli 3 times per day 12 weeks</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Climacteric symptoms&gt;=3 Points in Menopause Rating Scale (MRS) II

          -  Communication possible

        Exclusion Criteria:

          -  Hormone replacement therapy within 2 weeks prior to study inclusion

          -  Other complementary treatments 7 days before and during the study

          -  Climacteric symptoms caused by operation, chemotherapy or hormonal therapy of cancer

          -  Allergy to components of the remedy, especially bee poison
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelia U von Hagens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Complementary and Integrative Medicine</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-WÃ¼rttemberg</state>
        <zip>D-69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>von Hagens C, Schiller P, Godbillon B, Osburg J, Klose C, Limprecht R, Strowitzki T. Treating menopausal symptoms with a complex remedy or placebo: a randomized controlled trial. Climacteric. 2012 Aug;15(4):358-67. doi: 10.3109/13697137.2011.597895. Epub 2011 Oct 23.</citation>
    <PMID>22017387</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>June 12, 2018</last_update_submitted>
  <last_update_submitted_qc>June 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Cornelia von Hagens</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>menopausal symptoms</keyword>
  <keyword>complementary medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

